The RANKL/RANK pathway has been involved also in the pathogenesis of insulin resistance: accumulating evidences suggest that activation of the transcription factor NF-κB and the downstream inflammatory signaling pathways systematically and in the liver are key events in the etiology of hepatic insulin resistance and β-cell dysfunction [4–7]. This evidence concerns the gene TNFSF11 and Insulin resistance.